Extensive Cannabis Legalization Prompts the Rise of New Breath Detection Tech - Seite 2
Cannabix is using its FAIMS technology to isolate and detect ∆9-tetrahydrocannabinol ("THC"), a non-volatile compound, in breath. The Cannabix FAIMS marijuana breathalyzer device uses ion mobility filtering techniques (related to mass spectrometry – the gold standard analytical technique for molecular detection). The Cannabix device has been designed and built in a series of modules that together allow for sample intake, ionization, filtering and detection – all done under atmospheric pressure. In addition, the device has the ability to couple directly to a mass spectrometer in order to validate its detector responses.
It should be noted that a notice of allowance from the USPTO does not constitute a grant of patent. The Company will report on future material developments regarding its "Apparatus and Methods for Detection of Molecules" patent application in due course.
The Company has been steadily growing its intellectual property (IP) portfolio over recent months. In April, the Company received a notice of allowance for its patent application, No. 2887841 entitled, "Cannabis Drug Detection Device" from the Canadian Intellectual Property Office (CIPO). In addition, the Company was granted a granted patent No. 14/689434 entitled, "Cannabis Drug Detection Device" from the USPTO in January 2021. The newly received notice of allowance from the USPTO for its FAIMS related patent application builds on this IP momentum.
The Company expects to ship its THCBA to a clinic in the Northwestern, U.S. for beta testing in May. The collaborating clinic has a robust drug testing operation and is one of the top drug testing providers to employers within its respective state. The beta testing is focussed on improving user experience through testing and feedback and training the device's machine learning database."
For our latest "Buzz on the Street" Show featuring Cannabix Technologies Inc. recent corporate news, please head over to:
Sundial Growers Inc. (NASDAQ: SNDL) reported earlier this year that it has launched high-quality cannabis derivative products under the Top Leaf brand in response to rising consumer demands for solventless cannabis extracts. This most recent launch is consistent with Sundial's focus on premium inhalables, following branded retail offerings of flower, pre-roll and vape cartridges. "We made a strategic decision to produce these premium products based on demand for solventless, flavorful, pure, and potent cannabis concentrates from a growing group of consumers," said Andrew Stordeur, President and Chief Operating Officer of Sundial. "Our control of the entire manufacturing process from cultivation to extraction enables us to deliver premium quality products on a consistent basis. Adding bubble hash and other advanced concentrates to our product portfolio will expand Sundial's share of this rapidly expanding market segment."